Business Update

SciGen acquires chemotherapy, kidney drugs through technology transfer agreement with Intas

Published in Cancer Weekly, July 25th, 2006

Singapore biopharmaceutical company SciGen Limited (SIE) announced that it has secured the rights to manufacture, distribute and market GCSF, used to treat the symptoms of chemotherapy, and EPO, used to treat kidney disease, through a technology transfer agreement with Intas Pharmaceutical Ltd.

SciGen announced previously that it had signed an exclusive worldwide agreement with ACL Biopharm, Intas research and development partner, for the bulk supply of GCSF and EPO.

The technology transfer agreement will now allow SciGen to manufacture its own product supplies for commercialization using its existing and future sale and marketing channels. The world...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry